Role of Septal Myectomy in Pediatric Hypertrophic Cardiomyopathy
PDF
Cite
Share
Request
Review Article
VOLUME: 12 ISSUE: 3
P: 68 - 76
September 2024

Role of Septal Myectomy in Pediatric Hypertrophic Cardiomyopathy

J Updates Cardiovasc Med 2024;12(3):68-76
1. Westchester Medical Center; Maria Fareri Children’s Hospital; New York Medical College; Department of Surgery Division of Pediatric and Adult Congenital Cardiac Surgery, New York, United States
No information available.
No information available
Received Date: 03.07.2024
Accepted Date: 21.08.2024
Online Date: 15.10.2024
Publish Date: 15.10.2024
PDF
Cite
Share
Request

Abstract

Hypertrophic cardiomyopathy is a prevalent cause of sudden cardiac death among young people. This distinctive genetic condition can manifest at any age from infancy to adulthood. The primary features include unexplained left ventricular hypertrophy coupled with dynamic left ventricular outflow tract (LVOT) obstruction and a variable degree of mitral valve regurgitation. In certain cases, patients may also experience biventricular outflow tract obstruction. Surgical septal myectomy is the gold standard treatment for symptomatic children experiencing severe LVOT obstruction. This review focuses on surgical techniques for septal myectomy in pediatric patients and other adjunct procedures and summarizes the current outcomes.

Keywords:
Hypertrophic cardiomyopathy, sudden cardiac death, left ventricular outflow tract obstruction, asymmetrical septal hypertrophy, left ventricular myectomy

Introduction

Hypertrophic cardiomyopathy (HCM), formerly referred to as idiopathic hypertrophic subaortic stenosis, is a primary myocardial disorder with significant genetic component. This condition is marked by dynamic left ventricular outflow tract (LVOT) obstruction and asymmetrical hypertrophy of the interventricular septum (IVS). Although it is relatively rare in children compared with adults, HCM remains one of the leading causes of sudden cardiac death in younger populations. The clinical presentation varies widely from completely asymptomatic to exertional fatigue, chest pain, and/or dyspnea.

Medical management serves as the first-line approach for symptomatic individuals with LVOT obstruction(1); however, surgical septal myectomy should be considered for those who do not tolerate or respond adequately to medical therapies(2).

Morphological Variants

Various forms of septal hypertrophy exist within HCM, including basal (Figure 1), midventricular (Figure 2), and/or apical variants (Figure 3). Diffuse hypertrophy may also occur(3). Recognizing these patterns is crucial because they influence surgical decisions and approaches. For instance, the basal variant typically involves some degree of mitral valve regurgitation due to systolic anterior motion (SAM) affecting the anterior mitral valve leaflet (AML) (Figure 1). In apical cases, the left ventricular cavity tends to be considerably reduced without SAM.

Current Indications for Septal Myectomy

Surgical septal reduction continues to be the gold standard in children and young adults with severe LVOT obstruction (LVOT gradient ≥50 mmHg), intolerant to medical therapy, or who fail to respond to medications. In children, currently, there is no role for alcohol septal ablation or novel medical therapy that has been adopted recently in adults(4).

Surgery should also be considered in the presence of other pathophysiological problems, such as intrinsic mitral valve (MV) disease, fixed subaortic obstruction, and midventricular and/or apical involvement. 

Surgical Technique

As previously noted, the specific pattern of septal hypertrophy dictates the surgical approach necessary to effectively eliminate LVOT obstruction. The procedure typically commences via standard median sternotomy with central cannulation of both the aorta and right atrium. Bicaval cannulation may be used in younger children to enhance their exposure.

Prior to initiating cardiopulmonary bypass (CPB), we routinely assess the LVOT gradient through direct needle measurements taken from both the distal ascending aorta (Figure 4A) and the left ventricle via puncturing through the right ventricular free wall into the IVS (Figure 4B). Gradient assessment occurs at rest and with provocative maneuvers- most frequently through the induction of premature ventricular contractions (PVCs) using the Brockenbrough-Braunwald-Morrow maneuver-which serves to identify dynamic LVOT obstructions.

If PVC induction fails to reveal gradients satisfactorily, medications like isoproterenol may be used. Following CPB cessation, gradient measurements are repeated to ensure effective and complete myectomy and confirm the elimination of significant LVOT gradients (Figure 5B).

Surgical Approaches

Trans-aortic Approach

This method is particularly effective for basal variants of HCM(5, 6). After achieving cardioplegic arrest, a hockey-stick incision lower than the typical aortotomy utilized for standard aortic valve replacement-extending toward the non-coronary sinus is performed (Figure 6). The first critical step is to thoroughly evaluate the LVOT and to identify any abnormalities within the mitral subvalvular apparatus, such as anomalous chordae or papillary muscles. This is essential because it can cause persistent or recurrent LVOT obstruction.

The initial incision starts just beneath the nadir of the right coronary cusp while considering some distance from its base-this precaution helps prevent future cusp prolapse with subsequent aortic regurgitation (Figure 7). The incision is then directed anticlockwise toward the commissure between the right and left coronary cusps. After initial resection widens the subaortic space, better access to the left ventricle cavity and deeper visualization of the interventricular septum are achieved. The area of resection is then widened until a satisfactory enlargement of the left ventricular cavity is achieved.

Additional maneuvers that may enhance exposure include placing a sponge stick against the right ventricular free wall to enhance the visibility of the interventricular septum. This “extended myectomy” when compared with the initial “Morrow” technique, is characterized by its three-dimensional extension that ensures complete elimination of the gradient(7). Once satisfactory resection is achieved, the aortotomy is closed using a two-layer running suture, followed by a standard de-airing process and removal of the aortic cross-clamp.

Word of Caution for Children Undergoing Septal Myectomy

It can be challenging in children to perform transaortic myectomy due to the need to navigate through a small aortic root. The surgeon must exercise extreme caution when stretching the root/aortic valve during resection to avoid injuring the cusps or future aortic regurgitation.

Protecting the aortic valve during resection is paramount, and these are a few tips that can help facilitate the procedure:

Placement of the left ventricular vent through the left atrium ensures a dry field and better visualization and minimizes the need for suction through the aortic valve.

Placing a 5/0 or 6/0 polypropylene suture at the base of the cusp into the aortic sinus helps to retract the cusp away from the surgeon’s view without the need to add additional instruments through the small aortic root (Figure 8A).

The use of an aortic valve leaflet retractor can protect the cusp until the initial resection is completed, and the surgeon has adequate visualization of the left ventricular cavity (Figure 8B).

 After the initial resection, a small retractor can be placed through the created “trough” below the aortic valve to protect the cusp and facilitate retraction (Figure 8C).

Trans-Apical Myectomy

The transapical approach is particularly useful for the midventricular and apical variants of HCM. In these cases, achieving complete resection through the trans-aortic approach is challenging, if not impossible, especially in patients with small aortic annulus. The technical aspects of this approach have been described in detail elsewhere(8).

Briefly, after cardioplegic arrest, the incision for this approach is placed 1 cm lateral to the left anterior descending coronary artery (Figure 9A) and is more positioned on the left ventricular free wall anteriorly rather than on the actual apex (Figure 9B).

In the true apical variant of HCM, the left ventricular apex is completely obliterated with hypertrophied muscles, and in these cases, initial resection should be limited to the area of the IVS (Figure 9C) to avoid injury to the subvalvular apparatus of the MV, which is usually displaced apically in HCM cases.

After the identification of the left ventricular cavity, additional resection is performed to further enlarge the cavity. The apex is then closed in two layers supported by two strips of Teflon felt (Figure 9D).

Trans-Mitral Myectomy

This approach requires detachment of the anterior leaflet of the MV to expose the IVS, and once resection is completed, patch augmentation of the AML is usually required(9). One has to be familiar with the anatomy and visualization of the IVS through the MV, as it differs from the commonly used trans-aortic approach. This approach may be particularly useful in children and patients with a small aortic root in which resection and exposure via the transaortic approach are limited. A third potential benefit of this approach is that it allows the treatment of MV pathology and septal myectomy via one incision.

Adjunct Procedures for Left Ventricular Myectomy

Resection of Anomalous Papillary Muscles/Cordae

As described above, failure to recognize and address these MV abnormalities may result in persistent or recurrent LVOT obstruction(10, 11). In addition, these abnormalities can be difficult to detect on preoperative echocardiography; thus, the initial assessment of the LVOT is key. It is important to distinguish the anomalous from the true papillary muscle of the MV, with the major difference being that the former attaches to the body of the leaflet with no chordal attachment and can therefore be safely excised. Anomalous chordae are easily distinguished from the primary chordal structure of the MV because they insert into the septum and are not attached to the free leading edge of the leaflet. These limitations limit the AML mobility, leading to SAM. It is important to remember that no chordal attachment should occur between the MV apparatus and the IVS.

Unroofing of Associated Myocardial Bridging

Identification of myocardial bridging (MB) in patients with HCM can be challenging, and identifying those requiring unroofing can be even more challenging. There are no clear guidelines or recommendations regarding the best management approach for these patients.

Following septal myectomy, the mid-term results of different treatment modalities for MB in patients with HCM were reported by Wang et al.(12). There were 823 patients included, with 31 events identified (mortality in 24 and non-fatal myocardial infarction in 7) by the authors. The authors concluded that surgery for MB is advantageous when performed at the time of septal myectomy. Most patients, especially those presenting with chest pain in the setting of HCM, undergo coronary angiography. If a MB is identified, haemodynamic assessment of the bridge is done to determine if it is clinically significant, which will assist in decision-making for a concurrent unroofing procedure. Our technique of MB unroofing is performed via CPB and on the arrested heart in order not to inadvertently damage the coronary artery(13). Using sharp and electrocautery dissection, we unroof the entire bridged segment (Figure 10). It is important to note that the bridged segment of the coronary artery is fragile, and unroofing should be meticulously performed.

Left Ventricular Apical Aneurysm

Apical and pseudoaneurysms may occur in HCM. They are usually thin walls with varying sizes and can appear dyskinetic or akinetic. It occurs particularly in those with apical and midventricular variants (15-30% of patients)(14). Identification of these aneurysms is not always straightforward. In an analysis of 1332 patients with apical HCM, the diagnosis of concomitant apical aneurysms on echocardiography was missed in 64.5%(15).

Surgical resection of these aneurysms is recommended at the time of septal myectomy to minimize the risks of ventricular arrhythmias, heart failure, and/or sudden cardiac death, which have been reported in these cases(16).

Placement of Epicardial Internal Cardioverter Defibrillators

In the pediatric population, and due to the limitation of transvenous implantation of internal cardioverter defibrillators (ICD), it is not unusual to place an epicardial system at the end of the septal myectomy procedure (Figure 11). The indications include those with risk factors for sudden cardiac death, history of sustained ventricular tachycardia/fibrillation, and/or septal thickness ≥3 cm(17). Another option in children is placement of a subcutaneous system(18).

Right Ventricular Myectomy

A specific subset of patients with HCM, particularly those linked to genetic conditions such as Noonan syndrome, may exhibit biventricular outflow tract obstruction. Recognizing this condition is crucial during assessment, particularly when considering left-sided surgical myectomy.

The procedure for septal myectomy on the right side differs from that on the left; notably, due to the presence of septal attachment of the tricuspid valve on the right side. Therefore, caution must be exercised when shaving the IVS on the right side to prevent damage to both the conduction tissue and the tricuspid valve apparatus. Typically, this approach is achieved via an infundibular incision, followed by patch augmentation of the right ventricle outflow (Figure 12) tract(19).

Outcomes of Septal Myectomy in A Children

Children diagnosed with HCM often exhibit symptoms that resemble those seen in adults. These symptoms predominantly originate from a combination of diastolic dysfunction and notable mitral regurgitation. The initial signs of sudden death occur more frequently in children than in adults(20).

The surgical procedure is technically more complex for pediatric patients because of various anatomical challenges, particularly those related to the small size of the aortic annulus and the LVOT. A study conducted at the Mayo Clinic examined 127 patients aged 2-21 years who underwent septal myectomy. The findings indicated no early mortality; the most prevalent additional procedures included resection of accessory papillary muscles, repair of the MV, and closure of atrial-level shunts. Complications noted involved two cases of iatrogenic injury to the MV and seven cases involving injury to the aortic valve, all of which were successfully repaired. Additionally, they reported one case of an iatrogenic ventricular septal defect. Although there were four late fatalities, most patients experienced symptom improvement, with 96% classified within New York Heart Association class I or II. Six patients required repeat septal myectomy(21).

Recurrent Obstruction Following Septal Myectomy

In cases where complete and adequate septal myectomy is performed, recurrence rates tend to be low. As previously mentioned, it is essential to exclude anatomic factors contributing to recurrence-such as mitral subvalvular abnormalities involving anomalous papillary muscles and chordae-during the initial myectomy procedure to prevent reoperation or persistent symptoms.

Specific mechanisms leading to redo myectomy were identified in >50 patients: insufficient initial myectomy (especially critical in younger children), midventricular obstruction, and anomalous papillary muscles(22). The option for repeat septal myectomy remains both safe and viable; and it should continue to be considered the primary treatment modality for patients experiencing recurrent or persistent LVOT gradients following initial limited resection.

Conclusion

Extended left ventricular septal myectomy remains the gold standard for treating symptomatic children diagnosed with the obstructive variant of HCM. The trans-aortic and/or transapical approaches are most commonly used in this population, depending on the IVS morphology and the level of obstruction. Other adjunctive procedures that may be considered include concomitant unroofing of significant MB and placement of epicardial ICD in patients who meet the criteria. Concomitant right ventricular outflow tract obstruction, especially in patients with genetic syndromes. The outcomes remain excellent with low risk of recurrence if complete and satisfactory myectomy is initially performed.

References

1
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212-60.
2
Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg. 2017;6:329-36.
3
Said SM, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg. 2013;25:300-9.
4
Chase Cole J, Benvie SF, DeLosSantos M. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy. Clin Ther. 2024;46:368-73.
5
Said S, Marey G. Transaortic extended left ventricular septal myectomy in an adult with hypertrophic obstructive cardiomyopathy. Multimed Man Cardiothorac Surg. 2020;2020.
6
Said SM, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg. 2013;25:300-9.
7
Said SM. Commentary: Extended left ventricular septal myectomy for hypertrophic cardiomyopathy: The nuts and bolts. J Thorac Cardiovasc Surg. 2020;159:e299-e300.
8
Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27:443-8.
9
Matsuda H, Nomura F, Kadoba K, et al. Transatrial and transmitral approach for left ventricular myectomy and mitral valve plication for diffuse-type hypertrophic obstructive cardiomyopathy: a novel approach. J Thorac Cardiovasc Surg. 1996;112:195-6.
10
Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84:1188-97.
11
Said SM, Dearani JA, Ommen SR, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2013;11:617-27.
12
Wang S, Wang S, Lai Y, et al. Midterm results of different treatment methods for myocardial bridging in patients after septal myectomy. J Card Surg. 2021;36:501-8.
13
Said SM, Marey G, Hiremath GM. Unroofing of Myocardial Bridging After Septal Myectomy in a Child With Noonan Syndrome. World J Pediatr Congenit Heart Surg. 2021;12:659-60.
14
Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017;69:761-73.
15
Yang K, Song YY, Chen XY, et al. Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. Eur Heart J Cardiovasc Imaging. 2020;21:1341-50.
16
Nguyen A, Schaff HV. Electrical storms in patients with apical aneurysms and hypertrophic cardiomyopathy with midventricular obstruction: A case series. J Thorac Cardiovasc Surg. 2017;154:e101-3.
17
Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-73.
18
Francia P, Adduci C, Palano F, et al. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:893-9.
19
Said SM, Marey G, Hiremath GM. Unroofing of Myocardial Bridging After Septal Myectomy in a Child With Noonan Syndrome. World J Pediatr Congenit Heart Surg. 2021;12:659-60.
20
Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-4.
21
Arghami A, Dearani JA, Said SM, O’Leary PW, Schaff HV. Hypertrophic cardiomyopathy in children. Ann Cardiothorac Surg. 2017;6:376-85.
22
Minakata K, Dearani JA, Schaff HV, O‘Leary PW, Ommen SR, Danielson GK. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 2005;80:851-6.